iCardiac eCOA platform a 'major step forward,' says CEO

By Melissa Fassbender contact

- Last updated on GMT

iCardiac launches new eCOA platform QPoint
iCardiac’s new eCOA platform, QPoint, can measure clinical outcome assessments from patients at home or during site visits and will soon integrate with emerging wearables.

According to the company, study team members can customize study questionnaires and how they appear on devices in real time through its interactive study setup and validation portal RapidStart.

Alex Zapesochny, President and CEO of iCardiac Technologies, told us the platform has a number of technology features that sets it apart from others on the market​.

An important differentiator is our study setup simulator, which enables the eCOA vendor to efficiently and interactively create, review and test a study questionnaire in real time​,” he said. “Another key technology differentiator is the way the platform allows for a seamless study update or device replacement process​.”

Zapesochny explained the platform represents a major step forward for iCardiac, because it completes the company’s goal of to offer enabling innovation across all three of its service lines: cardiac safety​, eCOA, and respiratory testing.

It is also a step forward because, just like iCardiac was able to do in the field of cardiac safety, we believe the QPoint platform will set off a wave of innovation in the eCOA industry that will ultimately benefit all drug developers​,” added Zapesochny.

The company is currently working on the next set of features for QPoint and plans on extending the platform to integrate with emerging wearable and home-based diagnostic devices.

(Feature image: iStock/Rasulovs)

Related news

Show more

Related products


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers